SUBSCRIBE
SUBSCRIBE

Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS
Sep 21, 2020 Brisbane / CA / USA - BioMarin headquarters in Silicon Valley; BioMarin Pharmaceutical Inc. is an American biotechnology company
Mergers & acquisitions
BioMarin Pumps Up Revenue Goals With $4.8B Amicus Purchase
BioMarin Pharmaceutical has faced a rocky road, promising and then backing off revenue targets and cutting assets that have underperformed. But Amicus’ rare disease portfolio is already bringing in $600 million annually.
December 19, 2025
 · 
2 min read
 · 
Dan Samorodnitsky
Pulsing heart collage illustration, sign of life. Isolated human heart organ with glowing red line surrounding, black and white
Cardiovascular disease
Cytokinetics’ Moment of Truth: Can Aficamten Take On BMS in Hypertrophic Cardiomyopathy?
After 27 years in business, Cytokinetics hopes to pit its own cardiac myosin inhibitor against one it initially developed—now owned by Bristol Myers Squibb—in a market worth billions. Aficamten has a PDUFA date of Dec. 26.
December 19, 2025
 · 
5 min read
 · 
Dan Samorodnitsky
Balloon and missed bow spears arround . Target audience and marketing concept . This is a 3d render illustration .
Infectious disease
Insmed Delivers ‘Rare Disappointment’ as Brinsupri Flops in Mid-Stage Rhinosinusitis Study
Insmed pointed to a strong placebo response as the reason for the trial’s failure.
December 19, 2025
 · 
2 min read
 · 
Tristan Manalac
Cambridge, Massachusetts, USA - 30 July 2024. Takeda Pharmaceutical Company logo on office building.Biotech industry
Immunology and inflammation
Takeda’s $4B Nimbus Bet Pays Off With ‘Best-in-Class’ Phase III Plaque Psoriasis Data
With zasocitinib, Takeda is looking to challenge Bristol Myers Squibb’s kinase inhibitor Sotyktu, for which the Japanese pharma is running a head-to-head study in plaque psoriasis. Takeda expects to file for zasocitinib’s FDA approval next year.
December 19, 2025
 · 
2 min read
 · 
Tristan Manalac
Facade of Novo Nordisk's office in Fremont, California
Obesity
Novo Nordisk Files Combo Obesity Drug CagriSema For FDA Approval
The filing comes as Novo fights tooth-and-nail with rival Lilly to regain its footing at the top of the weight loss market.
December 18, 2025
 · 
2 min read
 · 
Dan Samorodnitsky
Deals
Inside the 2026 Biotech Landscape: Innovation, Investment and Global Momentum
In this episode of Denatured, Jennifer Smith-Parker speaks to Kenneth Galbraith, ⁠CEO of Zymeworks and Josh Smiley, president and COO of Zai Lab, about how renewed confidence is driving biotech entering 2026.
December 18, 2025
 · 
1 min read
 · 
BioSpace Insights
Cambridge, USA - 16 August 2024. View of Moderna office entrance with logo sign, Biotechnology industry
influenza
Moderna Scores $54 Million From CEPI To Fund Bird Flu Vaccine
The money replaces a small portion of a contract Moderna lost when the Department of Health and Human Services canceled $760 million in backing to develop the vaccine, called mRNA-1018.
December 18, 2025
 · 
1 min read
 · 
Dan Samorodnitsky
Weigh scales on pink background, top view with space for text. Overweight concept
Obesity
Lilly’s Obesity Pill Maintains Weight Loss as Estimated Approval Timelines Inch Closer
Participants in a Phase III trial who switched to Eli Lilly’s orforglipron after 72 weeks of treatment with Wegovy or Zepbound largely maintained their weight loss for up to a year.
December 18, 2025
 · 
2 min read
 · 
Tristan Manalac
Merck & Co. headquarters in Silicon Valley; Merck & Co. Inc. is an American multinational pharmaceutical company
Regulatory
FDA Mulls National Priority Vouchers for Two Potential Merck Blockbusters: Report
The tickets could go to the lipid-lowering pill enlicitide decanoate and the antibody-drug conjugate sacituzumab tirumotecan, though a spokesperson for the HHS did not confirm the news.
December 18, 2025
 · 
2 min read
 · 
Tristan Manalac
Load More
Visit website
Email Us
IN THE PRESS
Press Releases
Waters Sets a New Benchmark for Robustness and Sensitivity for High-Throughput Labs with the Xevo TQ Absolute XR Mass Spectrometer
June 2, 2025
 · 
4 min read
BioMidwest
Inotiv, Inc. Announces New Site Openings and Expansions Supporting Additional Capacity and Service Offerings
December 8, 2022
 · 
4 min read
Business
Parexel Announces Strategic Collaboration with Synexa Life Sciences and Drawbridge Health for COVID-19 Clinical Serology Testing Solution
November 2, 2020
 · 
4 min read
JOBS